eLife (Feb 2025)
The relationship between gut and nasopharyngeal microbiome composition can predict the severity of COVID-19
- Benita Martin-Castaño,
- Patricia Diez-Echave,
- Jorge García-García,
- Laura Hidalgo-García,
- Antonio Jesús Ruiz-Malagon,
- José Alberto Molina-Tijeras,
- María Jesús Rodríguez-Sojo,
- Anaïs Redruello-Romero,
- Margarita Martínez-Zaldívar,
- Emilio Mota,
- Fernando Cobo,
- Xando Díaz-Villamarin,
- Marta Alvarez-Estevez,
- Federico García,
- Concepción Morales-García,
- Silvia Merlos,
- Paula Garcia-Flores,
- Manuel Colmenero-Ruiz,
- José Hernández-Quero,
- Maria Nuñez,
- Maria Elena Rodriguez-Cabezas,
- Angel Carazo,
- Javier Martin,
- Rocio Moron,
- Alba Rodríguez Nogales,
- Julio Galvez
Affiliations
- Benita Martin-Castaño
- Centro de Salud Las Gabias, Distrito Granada-Metropolitano, Granada, Spain; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain
- Patricia Diez-Echave
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain
- Jorge García-García
- ORCiD
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain; Servicio Microbiología, Hospital Universitario Clínico San Cecilio, Granada, Spain
- Laura Hidalgo-García
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain
- Antonio Jesús Ruiz-Malagon
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain
- José Alberto Molina-Tijeras
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain
- María Jesús Rodríguez-Sojo
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain
- Anaïs Redruello-Romero
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain
- Margarita Martínez-Zaldívar
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Centro de Salud “Salvador Caballero”, Distrito Granada-Metropolitano, Granada, Spain
- Emilio Mota
- Centro de Salud “Salvador Caballero”, Distrito Granada-Metropolitano, Granada, Spain
- Fernando Cobo
- Servicio Microbiología, Hospital Universitario Virgen de las Nieves, Granada, Spain
- Xando Díaz-Villamarin
- ORCiD
- Instituto de Investigación Biosanitaria, Granada, Spain
- Marta Alvarez-Estevez
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Servicio Microbiología, Hospital Universitario Clínico San Cecilio, Granada, Spain; CIBER de Enfermedades Infecciosas (CIBER-Infecc), Instituto de Salud Carlos III, Madrid, Spain
- Federico García
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Servicio Microbiología, Hospital Universitario Clínico San Cecilio, Granada, Spain; CIBER de Enfermedades Infecciosas (CIBER-Infecc), Instituto de Salud Carlos III, Madrid, Spain
- Concepción Morales-García
- Respiratory Medicine Department, Hospital Universitario Virgen de las Nieves, Granada, Spain
- Silvia Merlos
- Respiratory Medicine Department, Hospital Universitario Virgen de las Nieves, Granada, Spain
- Paula Garcia-Flores
- Respiratory Medicine Department, Hospital Universitario Virgen de las Nieves, Granada, Spain
- Manuel Colmenero-Ruiz
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Servicio de Medicina Intensiva, Hospital Universitario Clínico San Cecilio, Granada, Spain
- José Hernández-Quero
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Servicio de Enfermedades Infecciosas, Hospital Universitario Clínico San Cecilio, Granada, Spain
- Maria Nuñez
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Servicio Farmacia Hospitalaria, Hospital Universitario Clínico San Cecilio, Granada, Spain; CIBER de Epidemiología y Salud Pública (CIBER-ESP), Instituto de Salud Carlos III, Madrid, Spain
- Maria Elena Rodriguez-Cabezas
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain
- Angel Carazo
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Servicio Microbiología, Hospital Universitario Clínico San Cecilio, Granada, Spain
- Javier Martin
- Department of Cell Biology and Immunology, Institute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain
- Rocio Moron
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Servicio Farmacia Hospitalaria, Hospital Universitario Clínico San Cecilio, Granada, Spain
- Alba Rodríguez Nogales
- ORCiD
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain
- Julio Galvez
- ORCiD
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain; CIBER de Enfermedades Hepáticas y Digestivas (CIBER-EHD), Instituto de Salud Carlos III, Madrid, Spain
- DOI
- https://doi.org/10.7554/eLife.95292
- Journal volume & issue
-
Vol. 13
Abstract
Coronavirus disease 2019 (COVID-19) is a respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that displays great variability in clinical phenotype. Many factors have been described to be correlated with its severity, and microbiota could play a key role in the infection, progression, and outcome of the disease. SARS-CoV-2 infection has been associated with nasopharyngeal and gut dysbiosis and higher abundance of opportunistic pathogens. To identify new prognostic markers for the disease, a multicentre prospective observational cohort study was carried out in COVID-19 patients divided into three cohorts based on symptomatology: mild (n = 24), moderate (n = 51), and severe/critical (n = 31). Faecal and nasopharyngeal samples were taken, and the microbiota was analysed. Linear discriminant analysis identified Mycoplasma salivarium, Prevotella dentalis, and Haemophilus parainfluenzae as biomarkers of severe COVID-19 in nasopharyngeal microbiota, while Prevotella bivia and Prevotella timonensis were defined in faecal microbiota. Additionally, a connection between faecal and nasopharyngeal microbiota was identified, with a significant ratio between P. timonensis (faeces) and P. dentalis and M. salivarium (nasopharyngeal) abundances found in critically ill patients. This ratio could serve as a novel prognostic tool for identifying severe COVID-19 cases.
Keywords